Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review

被引：20

作者：

Xu, Weilin ^{[1
]}

Chen, Xiu ^{[1
]}

Deng, Fei ^{[1
]}

Zhang, Jian ^{[1
]}

Zhang, Wei ^{[1
]}

Tang, Jinhai ^{[1
]}

机构：

[1] Nanjing Med Univ, Dept Gen Surg, Affiliated Hosp 1, Nanjing 210029, Peoples R China

来源：

ONCOTARGETS AND THERAPY | 2020年 / 13卷

基金：

中国国家自然科学基金;

关键词：

breast cancer; neoadjuvant; chemotherapy; response; predictor; TUMOR-INFILTRATING LYMPHOCYTES; PATHOLOGICAL COMPLETE RESPONSE; GROWTH-FACTOR; PROGNOSTIC BIOMARKER; IMAGING BIOMARKER; POOR-PROGNOSIS; DCE-MRI; EXPRESSION; THERAPY; SURVIVAL;

D O I：

10.2147/OTT.S253056

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Neoadjuvant chemotherapy (NAC) largely increases operative chances and improves prognosis of the local advanced breast cancer patients. However, no specific means have been invented to predict the therapy responses of patients receiving NAC. Therefore, we focus on the alterations of tumor tissue-related microenvironments such as stromal tumor-infiltrating lymphocytes status, cyclin-dependent kinase expression, non-coding RNA transcription or other small molecular changes, in order to detect potentially predicted biomarkers which reflect the therapeutic efficacy of NAC in different subtypes of breast cancer. Further, possible mechanisms are also discussed to discover feasible treatment targets. Thus, these findings will be helpful to promote the prognosis of breast cancer patients who received NAC and summarized in this review.

引用

页码：5887 / 5899

页数：13

共 117 条

[51] Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy [J].

Jhaveri, Komal ;

Teplinsky, Eleonora ;

Silvera, Deborah ;

Valeta-Magara, Amanda ;

Arju, Rezina ;

Giashuddin, Shah ;

Sarfraz, Yasmeen ;

Alexander, Melissa ;

Darvishian, Farbod ;

Levine, Paul H. ;

Hashmi, Salman ;

Zolfaghari, Ladan ;

Hoffman, Heather J. ;

Singh, Baljit ;

Goldberg, Judith D. ;

Hochman, Tsivia ;

Formenti, Silvia ;

Esteva, Francisco J. ;

Moran, Meena S. ;

Schneider, Robert J. .

CLINICAL BREAST CANCER, 2016, 16 (02) :113-122

[52]

Jin GC, 2015, INT J CLIN EXP PATHO, V8, P914

[53] Treatment Response to Preoperative Anthracycline-Based Chemotherapy in Locally Advanced Breast Cancer: The Relevance of Proliferation and Apoptosis Rates [J].

Kanjer, Ksenija ;

Tatic, Svetislav ;

Neskovic-Konstantinovic, Zora ;

Abu Rabi, Zaki ;

Nikolic-Vukosavljevic, Dragica .

PATHOLOGY & ONCOLOGY RESEARCH, 2013, 19 (03) :577-588

[54] Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy [J].

Kim, Hyori ;

Youk, Jeonghwan ;

Yang, Yaewon ;

Kim, Tae-Yong ;

Min, Ahrum ;

Ham, Hye-Seon ;

Cho, Seongcheol ;

Lee, Kyung-Hun ;

Keam, Bhumsuk ;

Han, Sae-Won ;

Oh, Do-Youn ;

Ryu, Han Suk ;

Han, Wonshik ;

Park, In Ae ;

Kim, Tae-You ;

Noh, Dong-Young ;

Im, Seock-Ah .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (03) :707-714

[55] Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers [J].

Kim, S. J. ;

Nakayama, S. ;

Shimazu, K. ;

Tamaki, Y. ;

Akazawa, K. ;

Tsukamoto, F. ;

Torikoshi, Y. ;

Matsushima, T. ;

Shibayama, M. ;

Ishihara, H. ;

Noguchi, S. .

ANNALS OF ONCOLOGY, 2012, 23 (04) :891-U3

[56] Amide chemical exchange saturation transfer at 7 T: a possible biomarker for detecting early response to neoadjuvant chemotherapy in breast cancer patients [J].

Krikken, Erwin ;

Khlebnikov, Vitaliy ;

Zaiss, Moritz ;

Jibodh, Rajni A. ;

van Diest, Paul J. ;

Luijten, Peter R. ;

Klomp, Dennis W. J. ;

Van Laarhoven, Hanneke W. M. ;

Wijnen, Jannie P. .

BREAST CANCER RESEARCH, 2018, 20

[57] Diagnostic Performance of Magnetic Resonance Imaging for Assessing Tumor Response in Patients With HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy is Associated With Molecular Biomarker Profile [J].

Kuzucan, Aida ;

Chen, Jeon-Hor ;

Bahri, Shadfar ;

Mehta, Rita S. ;

Carpenter, Philip M. ;

Fwu, Peter T. ;

Yu, Hon J. ;

Hsiang, David J. B. ;

Lane, Karen T. ;

Butler, John A. ;

Feig, Stephen A. ;

Su, Min-Ying .

CLINICAL BREAST CANCER, 2012, 12 (02) :110-118

[58] Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer [J].

Layman, Rachel M. ;

Thomas, Dafydd G. ;

Griffith, Kent A. ;

Smerage, Jeffrey B. ;

Helvie, Mark A. ;

Roubidoux, Marilyn A. ;

Diehl, Kathleen M. ;

Newman, Lisa A. ;

Sabel, Michael S. ;

Hayman, James A. ;

Pierce, Lori J. ;

Hayes, Daniel F. ;

Schott, Anne F. .

CLINICAL CANCER RESEARCH, 2007, 13 (14) :4092-4097

[59] Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy [J].

Lee, Kutei C. ;

Moffat, Bradford A. ;

Schott, Anne F. ;

Layman, Rachel ;

Ellingworth, Steven ;

Juliar, Rebecca ;

Khan, Amjad P. ;

Helvie, Mark ;

Meyer, Charles R. ;

Chenevert, Thomas L. ;

Rehemtulla, Alnawaz ;

Ross, Brian D. .

CLINICAL CANCER RESEARCH, 2007, 13 (02) :443-450

[60] Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer [J].

Li, Xiaoxian Bill ;

Krishnamurti, Uma ;

Bhattarai, Shristi ;

Ktimov, Sergey ;

Reid, Michelle D. ;

O'Regan, Ruth ;

Aneja, Ritu .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2016, 145 (06) :871-878

← 1 2 3 4 5 6 7 8 9 10 →